当前位置:首页 >财报库 > 报告详情

费森尤斯Fresenius(FMS)2023年年度报告「NYSE」(英文版)(381页).pdf

上传人: Y**** 编号:654159 2024-05-21 381页 9.23MB

下载:

1、ANNUAL REPORT 2023Group in figures Table of contentsMedia HubTargets,results,and outlookFresenius is a global healthcare company.We offer system-critical products and services for therapies for care of critically and chronically ill patients.Fresenius com-prises the Operating Companies Fresenius Kab

2、i and Fresenius Helios as well as the Investment Companies Fresenius Vamed and Fresenius Medical Care.Operating CompaniesInvestment CompaniesFront page2Fresenius|Annual Report 2023Group in figures Table of contentsMedia HubTargets,results,and outlook in millions20232022202120202019 Revenue and earni

3、ngsRevenue 1 22,299 21,532 19,969 18,476 17,993 EBITDA 1,2 3,422 3,315 3,353 3,042 3,191 EBIT 1,2 2,262 2,190 2,337 2,113 2,332 Net income 1,2,3 1,505 1,729 1,8671,7961,879Depreciation and amortization 1,2 1,160 1,125 1,016 929 859 Earnings per share in 1,2,32.673.083.353.223.37Cash flow and balance

4、 sheetOperating cash flow 1 2,131 2,031 2,589 2,316 1,696 Free cash flow before acquisitions,dividends and lease liabilities 1 1,024 9421,401986376Free cash flow after acquisitions,dividends and lease liabilities 1 115-31838818-394Cash conversion rate 1 1.0 0.90.90.80.5Total assets45,284 76,400 71,9

5、62 66,646 67,006 Non-current assets32,764 58,121 54,501 50,874 51,742 Equity 4 19,651 32,218 29,288 26,023 26,580 Equity ratio 443%42%41%39%40%Net debt 1 13,268 13,316 12,650 13,021 12,980 Net debt/EBITDA 1,2,5 3.76 3.80 3.64 4.12 3.93 Investments 1,6 1,346 2,015 1,635 1,841 1,664 ProfitabilityEBIT

6、margin 1,210.1%10.2%11.7%11.4%13.0%Return on invested capital(ROIC)1,25.2%5.6%6.2%5.9%6.7%Dividend per share in 0.920.920.880.84Employees(December 31)1193,865 188,876 185,827 178,140 165,834 1 Prior-year figures have been adjusted due to the application of IFRS 5 to the deconsolidated operations of

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据Fresenius 2023年年报的内容,我总结了以下关键点: 1. Fresenius是一家全球医疗保健公司,提供治疗重症和慢性疾病患者的系统关键产品和服务。 2. 2023财年,Fresenius的营收约为223亿欧元,同比增长6%,EBITDA约为34.2亿欧元,同比增长2%。 3. Fresenius完成了对Fresenius Medical Care的解体,两家公司现在独立运营,决策更快,更专注于各自的核心业务。 4. Fresenius Kabi和Fresenius Helios在2023财年表现良好,实现了承诺的市场表现。 5. Fresenius计划到2025年通过成本节约减少4亿欧元债务,并计划到2024年实现盈利增长。 6. Fresenius致力于通过人工智能、数字化、机器人和细胞基因治疗等前沿技术改善人们的健康。 7. Fresenius在2023年已经减少了22%的碳排放,并计划到2030年将碳排放减半,到2040年实现碳中和。
弗雷森尤斯2023年财报亮点有哪些? 弗雷森尤斯如何应对全球经济挑战? 弗雷森尤斯在医疗保健领域有哪些创新?
客服
商务合作
小程序
服务号
折叠